Medication info

Empagliflozin/Metformin Hydrochloride Tablets 12.5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Biconvex oval film-coated tablet with a light brownish purple hue.
Packaging
60 tablets/box [(10 tablets/PTP x 6)], 10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/bottle
Approval status
Active

MFDS item code 202302540 · Approved 2023.08.28

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you forget to take this medicine, take it as soon as you remember. However, do not take a double dose at one time; skip the missed dose. No dose adjustment is needed in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) less than 60ml/min/1.73m2 [or creatinine clearance (CrCl) < 60 ml/min]. Because this medicine contains metformin, it must not be administered to patients with an eGFR less than 45 ml/min/1.73m2 or CrCl less than 45 ml/min. This medicine may be administered only to patients with an eGFR of 45-59 ml/min/1.73m2 or CrCl of 45-59 ml/min who tolerate empagliflozin well and have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500mg or 850mg once daily, and the maximum dose is 500 mg twice daily; the dose of empagliflozin that may be administered is 10mg once daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 m/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Poor blood glucose control
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to improve blood glucose control in adults with type 2 diabetes when used in conjunction with diet and exercise. It is particularly effective in patients whose blood glucose is not sufficiently controlled, and should be administered with reference to specialist guidance if cardiovascular disease is present. Therefore, this medication is used to aid in diabetes treatment and improve blood glucose management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you forget to take this medicine, take it as soon as you remember. However, do not take a double dose at one time; skip the missed dose. No dose adjustment is needed in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) less than 60ml/min/1.73m2 [or creatinine clearance (CrCl) < 60 ml/min]. Because this medicine contains metformin, it must not be administered to patients with an eGFR less than 45 ml/min/1.73m2 or CrCl less than 45 ml/min. This medicine may be administered only to patients with an eGFR of 45-59 ml/min/1.73m2 or CrCl of 45-59 ml/min who tolerate empagliflozin well and have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500mg or 850mg once daily, and the maximum dose is 500 mg twice daily; the dose of empagliflozin that may be administered is 10mg once daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 m/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into account.

Precautions

This medication is composed of two ingredients that aid in blood glucose control. During the use of this medication, there may be a rare side effect called severe lactic acidosis, so attention to symptoms is necessary. Especially, when taken concurrently with insulin or sulfonylurea medications, hypoglycemia may occur, so caution is required. This medication should not be administered to patients with moderate to severe renal impairment, nor should it be used in cases of acute kidney problems or serious infections. Additionally, it should not be administered to patients with type 1 diabetes, diabetic ketoacidosis, or acute and unstable heart failure. Before and after examinations using iodine contrast agents, administration of this medication should be temporarily suspended, and it should be resumed only after confirming normal renal function. It is also safer for women who are pregnant or breastfeeding to avoid using this medication. Regular monitoring of renal function should be conducted before and during treatment, especially in elderly patients or those with slight renal impairment, as increased caution is necessary. Adverse effects such as gastrointestinal disturbances, urinary tract infections, reproductive infections, hypoglycemia, increased urination, etc., may occur; therefore, if any unusual symptoms occur, immediate consultation with a physician is advised. Alcohol consumption may increase the risk of lactic acidosis, so it is advised to avoid it during treatment. If surgery is planned or an acute illness arises, one should consult with a physician regarding the temporary cessation of medication use. This medication may increase the risk of hypoglycemia, so dosage adjustments may be needed when used with insulin or other blood glucose-lowering agents. Furthermore, patients at risk of fluid loss or dehydration should be closely monitored for hydration status and blood pressure during treatment. During the use of this medication, it is important to regularly check liver function, renal function, and vitamin B12 levels through blood tests. It is not recommended for children or adolescents under 18 years of age, as safety and efficacy have not been established. In case of overdose, one should immediately visit the hospital for appropriate treatment, and particularly, if symptoms of lactic acidosis appear, immediate emergency treatment is required. This medication should be stored out of reach of children, and it is important to keep it in its original container to maintain quality.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • decreased fluid volume
  • nausea
  • vomiting
Show 69 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vulvovaginitis
  • balanitis
  • perineal necrosis
  • increased serum creatinine
  • decreased glomerular filtration rate
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • bowel hemorrhage
  • chronic gastritis
  • various neurological disorders
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • cervical inflammation
  • hypercholesterolemia
  • dyslipidemia
  • vitamin D deficiency
  • nasopharyngitis
  • headache
  • dizziness
  • insomnia
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • otalgia
  • orthostatic dizziness
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • vulvar pruritus
  • genital pruritus
  • hyperglycemia
  • hyponatremia
  • back pain
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a long time.

Appearance and packaging

Appearance

Biconvex oval film-coated tablet with a light brownish purple hue.

Package unit

60 tablets/box [(10 tablets/PTP x 6)], 10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.